Assembly Biosciences (NASDAQ:ASMB) Upgraded to “Strong-Buy” at Zacks Research

Assembly Biosciences (NASDAQ:ASMB) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other research firms also recently issued reports on ASMB. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Tuesday. Mizuho set a $45.00 target price on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Assembly Biosciences Stock Performance

ASMB stock opened at $34.38 on Thursday. The stock’s 50 day simple moving average is $27.11 and its 200 day simple moving average is $27.60. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71. The company has a market cap of $700.01 million, a P/E ratio of 33.71 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The firm had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Equities analysts predict that Assembly Biosciences will post 2.28 earnings per share for the current year.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new position in Assembly Biosciences during the 2nd quarter valued at $660,000. Bank of America Corp DE grew its stake in shares of Assembly Biosciences by 113.3% in the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 5,792 shares in the last quarter. Stempoint Capital LP grew its stake in shares of Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after acquiring an additional 28,707 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Assembly Biosciences by 1.4% in the first quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after purchasing an additional 11,384 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Assembly Biosciences by 69.4% in the first quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 6,411 shares during the last quarter. 19.92% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.